Logo_final_color.png
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
September 16, 2024 06:30 ET | Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
MetasTx-Logo_HoRes.jpg
Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures
September 12, 2024 06:58 ET | MetasTx LLC
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
factMR-logo.png
Gamification Mobile Application in Healthcare Market is Expected to Hit US$ 31,168.1 Million by 2034 | Fact.MR Report
September 12, 2024 06:00 ET | FACT.MR
Rockville, MD, Sept. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global gamification mobile application in healthcare market is...
Radiance BioPharma sponsoring Investor Cruise Event 2024
August 29, 2024 15:30 ET | Radiance BioPharma
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced...
Federal report illum
Federal report illuminates need for disability inclusion in clinical trials
August 14, 2024 12:18 ET | National Council on Disability
WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Today, the National Council on Disability (NCD) released a timely report on exclusionary practices that prevent people with disabilities from...
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
May 22, 2024 08:30 ET | Biodexa Pharmaceuticals PLC
May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking...
WUGEN-Logo-White-Background-FIN.jpg
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
May 20, 2024 07:03 ET | Wugen
Wugen Announces RMAT and PRIME Designations for WU-CART-007 and Plans to Present Positive Phase 2 Study Findings at EHA 2024
Tourmaline_logo.jpg
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024 07:00 ET | Tourmaline Bio, Inc.
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial